Description
Biocompatibles International plc is a leading company in the field of drug-device combination products. The Oncology Products Division conducts the marketing of Biocompatibles’ approved oncology products. These include products that are used for the treatment of primary liver cancer (HCC), liver metastases from colorectal cancer and prostate cancer. Our R&D Facilities are engaged in licensing and in new product development for oncology, stroke, and diabetes and obesity. We have collaborative agreements with AstraZeneca, Bayer Healthcare Pharmaceuticals Inc. and Medtronic Inc.
Share Price
Recent Biocompatibles news
- 26/08/2010 Biocompatibles International turns profitable in H1, reports positive results from DEBIRI trial
- 06/07/2010 Biocompatibles buys out bead products patent license for US$4.5m
- 24/06/2010 Edison Investment Research notes progress at Biocompatibles, supports revenues forecasts
- 16/06/2010 Biocompatibles forecasts profitability from H1 and raises guidance for full year
- 25/03/2010 Edison Investment Research discusses Biocompatibles valuation
Presentations & Company Media
Related Research & Media
No Documents available.
Company Statement:
Biocompatibles is a leading medical technology company in the field of drug device combination products. We operate through an Oncology Products Division and two R&D businesses.
Our “Business Model” is to own the most valuable products in our portfolio and pipeline; and to engage with partners where their scale and/or focus offers more effective execution. In this context we have important relationships with some of the world’s most successful healthcare companies, including Medtronic, AstraZeneca, Bayer and Eisai.
We consider ourselves to be the leader in the field of Drug-Eluting Beads for the treatment of cancer and amongst the leaders in the field of stem cell derived therapies for the brain. Our task is to develop these leading technology positions into really attractive market positions or valuable licence agreements.
The Vision
Our Vision for Biocompatibles remains the development of a high margin, high growth, financially strong business based on a range of valuable drug device combination products.
The Vision of the Oncology Products and Drug Delivery businesses is also unchanged - the creation and leadership of a market for Drug-Eluting Beads and the recognition of our products as a Gold Standard treatment for Hepatocellular Carcinoma and Metastatic Colo-Rectal Cancer. CellMed’s Vision is still to be first to market with an engineered stem cell product - the Drug-Eluting CellBead for the treatment of stroke. We believe that in 2008 we took substantial steps towards the realisation of these visions.
Current Operations:
Bead Block
Bead Block is an embolic device intended for the purpose of embolising the blood vessels of a variety of hypervascularised tumours (e.g. uterine fibroids) and arteriovenous malformations. Bead Block is a preformed, deformable microsphere consisting of a biocompatible, acrylamido polyvinyl alcohol macromer.
Bead Block compressible microspheres are used in embolisation therapy. This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. By blocking the blood supply to the target area, the tumour or malformation is starved of nutrients and shrinks in size.
For more information on the Bead Block, product please click here
DC Bead
DC Bead, a Drug-Eluting Bead, is a drug delivery embolisation system, intended to be loaded with a drug for the purpose of treating a variety of malignant hypervascularised tumours (e.g. hepatocellular carcinoma).
DC Bead is a drug delivery embolisation system for use in trans-arterial chemoembolisation (TACE).
This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. DC Bead microspheres are produced from a biocompatible polyvinyl alcohol (PVA) hydrogel that has been modified with sulphonate groups for the controlled loading and delivery of chemotherapeutic drugs. DC Bead occludes the blood flow to the target tissue and delivers a local and sustained dose of drug direct to the tumour.
For more information on the DC Bead product, please click here
LC Bead
LC Bead is a controlled embolisation system intended for the purpose of embolising the blood vessels of a variety of hypervascularised tumours and arteriovenous malformation. LC Bead is a preformed, deformable microsphere consisting of a biocompatible, sulphonate- modified, N-Fil hydrogel.
For more information on the DC Bead Product, please click here
The Pipeline
Biocompatibles Drug-Eluting Bead technology is supported by a comprehensive programme of clinical trials designed to confirm our products' superior clinical benefits. Current pre-clinical and clinical trials evidence benefits in terms of efficacy, survival, tolerability and safety in a number of cancers. Future developments in Drug-Eluting Bead technology targets new therapeutic areas where biological drug delivery or biodegradability is required or advantageous.
PRECISION Bead
PRECISION Bead, a Drug Eluting Bead, is an embolisation system loaded with doxorubicin intended for the purpose of treating Hepatocellular Carcinoma. PRECISION Bead is a preformed, deformable microsphere that occludes the blood flow to the target tissue and can release a local, controlled and sustained dose of drug directly to the tumour. PRECISION Bead consists of a biocompatible, sulphonate-modified, N-Fil hydrogel, loaded with a precise dose of doxorubicin.
To download the Precision Bead Brochure, Please click Here
PARAGON Bead
PARAGON Bead is a Drug-Eluting Bead loaded with irinotecan and has entered clinical evaluation. It is intended for the treatment of liver metastases of the colon.
Cell Bead
Cell Bead is a bead in development for the encapsulation of cells or tissues for long term biologic drug delivery.
Biodegradable Bead
Biodegradable Bead is a bead being developed to offer delivery solutions where biodegradability of the bead is a requirement or an advantage.
For more information for Biocompatibles pipeline products, please click here
Bead Block
Bead Block is an embolic device intended for the purpose of embolising the blood vessels of a variety of hypervascularised tumours (e.g. uterine fibroids) and arteriovenous malformations. Bead Block is a preformed, deformable microsphere consisting of a biocompatible, acrylamido polyvinyl alcohol macromer.
Bead Block compressible microspheres are used in embolisation therapy. This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. By blocking the blood supply to the target area, the tumour or malformation is starved of nutrients and shrinks in size.
For more information on the Bead Block, product please click here
DC Bead
DC Bead, a Drug-Eluting Bead, is a drug delivery embolisation system, intended to be loaded with a drug for the purpose of treating a variety of malignant hypervascularised tumours (e.g. hepatocellular carcinoma).
DC Bead is a drug delivery embolisation system for use in trans-arterial chemoembolisation (TACE).
This is a minimally invasive (non-surgical) procedure performed by an interventional radiologist. DC Bead microspheres are produced from a biocompatible polyvinyl alcohol (PVA) hydrogel that has been modified with sulphonate groups for the controlled loading and delivery of chemotherapeutic drugs. DC Bead occludes the blood flow to the target tissue and delivers a local and sustained dose of drug direct to the tumour.
For more information on the DC Bead product, please click here
LC Bead
LC Bead is a controlled embolisation system intended for the purpose of embolising the blood vessels of a variety of hypervascularised tumours and arteriovenous malformation. LC Bead is a preformed, deformable microsphere consisting of a biocompatible, sulphonate- modified, N-Fil hydrogel.
For more information on the DC Bead Product, please click here
The Pipeline
Biocompatibles Drug-Eluting Bead technology is supported by a comprehensive programme of clinical trials designed to confirm our products' superior clinical benefits. Current pre-clinical and clinical trials evidence benefits in terms of efficacy, survival, tolerability and safety in a number of cancers. Future developments in Drug-Eluting Bead technology targets new therapeutic areas where biological drug delivery or biodegradability is required or advantageous.
PRECISION Bead
PRECISION Bead, a Drug Eluting Bead, is an embolisation system loaded with doxorubicin intended for the purpose of treating Hepatocellular Carcinoma. PRECISION Bead is a preformed, deformable microsphere that occludes the blood flow to the target tissue and can release a local, controlled and sustained dose of drug directly to the tumour. PRECISION Bead consists of a biocompatible, sulphonate-modified, N-Fil hydrogel, loaded with a precise dose of doxorubicin.
To download the Precision Bead Brochure, Please click Here
PARAGON Bead
PARAGON Bead is a Drug-Eluting Bead loaded with irinotecan and has entered clinical evaluation. It is intended for the treatment of liver metastases of the colon.
Cell Bead
Cell Bead is a bead in development for the encapsulation of cells or tissues for long term biologic drug delivery.
Biodegradable Bead
Biodegradable Bead is a bead being developed to offer delivery solutions where biodegradability of the bead is a requirement or an advantage.
For more information for Biocompatibles pipeline products, please click here
Management
Board of Directors
For more information click here
Gerry Brown - Chairman and Non-Executive Director
Crispin Simon - Chief Executive
Ian Ardill - Finance Director & Company Secretary
Jeremy Curnock Cook - Senior Independent Non-Executive Director
Anne Fairey, BM, FRCP, MFPM (Dis) - Independent non-executive director
Sir Thomas Harris - Independent Non-Executive Director
Peter Stratford - Managing Director, Drug Delivery Division
John Sylvester - Managing Director, International Division
Anthony Weir - Independent Non-Executive Director
Major Shareholders
For investor information click here
Contact Information
Biocompatibles
Chapman House
Farnham Business Park
Weydon Lane
Farnham, Surrey
GU9 8QL UK
Tel No: +44 (0)1252 732 732
Fax No: +44 (0)1252 732 777
Corporate Information
Stockbrokers
Piper Jaffray Limited
1 South Place
London
EC2M 2RB
Investors interested in Biocompatibles recently viewed:
- Access Pharmaceuticals (OTCBB: ACCP)
- Advanced Cell Technology (OTCBB: ACTC)
- Alliance Pharma (AIM: APH)
- Amphion Innovations (LON: AMP)
- Asterand (LSE: ATD)
- BioNeutral Group (OTCBB: BONU)
- Bionomics (ASX: BNO)
- Circadian Technologies Limited (ASX: CIR)
- CogState (ASX: CGS)
- e-Therapeutics plc (AIM: ETX)
- Eco Animal Health Group Plc (AIM: EAH)
- Epistem (AIM: EHP)
- ImmuPharma PLC (AIM: IMM)
- Lipoxen (AIM: LPX)
- Medical Australia Limited (ASX: MLA)
- Oxford Nutrascience (AIM: ONG)
- Renovo Group Plc (LSE: RNVO)
- Rexahn Pharmaceuticals (AMEX: RNN)
- Silence Therapeutics (AIM: SLN)
- Starpharma (ASX: SPL)
- Stirling Products Limited (ASX: STI)
